Navigation Links
Wyeth Announces Holder Right to Surrender Convertible Debentures
Date:6/16/2009

the value of the shares of Common Stock that holders of Convertible Debentures would be entitled to receive upon conversion, if eligible for conversion pursuant to the Indenture, would be $749.75 per $1,000 aggregate principal amount at maturity of Convertible Debentures outstanding. Wyeth intends to settle the entire amount of any conversion of the Convertible Debentures in cash.

The Bank of New York Mellon, the Trustee for the Convertible Debentures, has informed the Company that, as of the date of this communication, all custodians and beneficial holders of the Convertible Debentures hold the Convertible Debentures through accounts with The Depository Trust Company ("DTC") and that there are no certificated Convertible Debentures in non-global form. Accordingly, all Convertible Debentures surrendered for purchase must be delivered through the transmittal procedures of DTC.

The Trustee is acting both as the Paying Agent and Conversion Agent, each as defined under the Indenture, for purposes of the purchase option. In order to receive the purchase price for the Convertible Debentures, a holder must conform with the procedural requirements of the Company Notice, including presenting the Convertible Debentures for surrender to the Paying Agent on or before 5:00 p.m., New York City time, on July 14, 2009 at: The Bank of New York Mellon, 101 Barclay Street, 8W, New York, New York 10286, Attention: Global Corporate Finance.

A Company Notice detailing the purchase option is being sent by the Trustee on behalf of the Company to DTC as sole record owner of Convertible Debentures. Copies of the Company Notice and additional information related to the procedures for the purchase option may be obtained from the Trustee by calling 1-800-275-2048.

About Wyeth

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discov
'/>"/>

SOURCE Wyeth
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Wyeth Declares Common Stock Dividend
2. New Phase 3 Data Continue to Indicate that Wyeths Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
3. Wyeth Sets Webcast and Conference Call For 2009 Second Quarter Earnings
4. Wyeth Announces Full Redemption of $2 Convertible Preferred Stock
5. Wyeth Declares Common and Preferred Stock Dividends
6. Wyeth Sets Webcast and Conference Call for 2009 First Quarter Earnings
7. Wyeth to Present at the SG Cowen & Co. 29th Annual Healthcare Conference
8. Wyeth to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
9. Wyeth Names Michael Kamarck President, Technical Operations & Product Supply
10. Wyeth Declares Preferred Stock Dividend
11. Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015  Brooklyn residents now have a new ... pain and injuries. Nunzio Saulle , M.D., a ... of his NJS Physical Medicine and Rehabilitation (PM&R) practice ... March 5, 2015. Health Plus Management, LLC is managing ... at 1178 Flatbush Avenue. This new PM&R practice will ...
(Date:3/4/2015)... March 4, 2015 /CNW/ - Resverlogix Corp. (TSX:RVX) ... completed a collaborative research program with Emerald ... Fast Collective Evolution Technology (FACET), Emerald Logic ... measurements obtained from each of 798 patients ... clinical trials ASSERT, SUSTAIN and ASSURE. The ...
(Date:3/4/2015)... Pa. , March 4, 2015 /PRNewswire/ ... services and technology provider, today announced that ... 10 countries convened at its annual European ... to discuss the use of ... challenges. BioClinica,s eClinical technologies include: the Microsoft ...
(Date:3/4/2015)... 2015 Lancée par ... en décembre 2011, l,étude collaborative française ... qui compare   l es microsphères en ... dans le carcinome hépatocellulaire avancé, a recruté plus ... avancé   ; les résultats sont attendus fin ...
Breaking Biology Technology:NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6
... /Xinhua-PRNewswire-FirstCall/ -- American Oriental,Bioengineering, Inc. (NYSE: AOB ), ... manufacture and commercialization,of a broad range of prescription and ... the Company will present at the following,conferences:, ... held at the Grand Hyatt ...
... Agreement will enable HGS to generate revenue from available ... manufacturing capacity -, - Revenue potential from manufacturing alliances, including the alliance, ... ... years -, ROCKVILLE, Md., Sept. 4 Human Genome,Sciences, Inc. (Nasdaq: HGSI ) ...
... -- Company Maintains Full Year Guidance, ... International Limited (NYSE: MR ), a ... worldwide today announced its selected,unaudited financial results ... 2008.,During the quarter, Mindray successfully completed the ...
Cached Biology Technology:American Oriental Bioengineering Announces Participation in September Investor Conferences 2Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira 2Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira 3Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira 4Mindray Medical International Announces Second Quarter 2008 Results 2Mindray Medical International Announces Second Quarter 2008 Results 3Mindray Medical International Announces Second Quarter 2008 Results 4Mindray Medical International Announces Second Quarter 2008 Results 5Mindray Medical International Announces Second Quarter 2008 Results 6Mindray Medical International Announces Second Quarter 2008 Results 7Mindray Medical International Announces Second Quarter 2008 Results 8Mindray Medical International Announces Second Quarter 2008 Results 9Mindray Medical International Announces Second Quarter 2008 Results 10Mindray Medical International Announces Second Quarter 2008 Results 11Mindray Medical International Announces Second Quarter 2008 Results 12Mindray Medical International Announces Second Quarter 2008 Results 13Mindray Medical International Announces Second Quarter 2008 Results 14Mindray Medical International Announces Second Quarter 2008 Results 15Mindray Medical International Announces Second Quarter 2008 Results 16Mindray Medical International Announces Second Quarter 2008 Results 17
(Date:2/12/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announced ... DISTRIBUTED METHOD AND SYSTEM TO IMPROVE COLLABORATIVE ... establishes NXT-ID,s position in the emerging "Internet of Things" ... for multiple devices to collaborate with one another to ...
(Date:2/5/2015)... PARK, North Carolina , 5. Februar ... 35. Jahr als spezialisiertes Logistikunternehmen und hat ... als einzige klinische Logistikfirma (Clinical Logistics Organization ... Kernbotschaft der neuen Kampagne lautet First ... Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... open letter addressed to President Barack Obama and the ... that the currently stated objectives in limiting the climatic ... to take clear leadership towards meet the objectives of ... to avert a "global climatic catastrophe". ...
... animals ever to have walked the face of the earth ... a paper published today in the Zoological Society of London,s ... the original statistical model used to calculate dinosaur mass is ... for the mass of Apatosaurus louisae , one of ...
... (June 21, 2009) Notch signaling helps determine the fate ... of organisms, including humans. In an article that appears in ... at Baylor College of Medicine report that a new finding ... in the fruit fly could explain the mystery behind an ...
Cached Biology News:Leading scientists and scholars urge action on climate issues 2Fate in fly sensory organ precursor cells could explain human immune disorder 2Fate in fly sensory organ precursor cells could explain human immune disorder 3